vs
Side-by-side financial comparison of Mayville Engineering Company, Inc. (MEC) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
Mayville Engineering Company, Inc. is the larger business by last-quarter revenue ($134.3M vs $129.7M, roughly 1.0× Travere Therapeutics, Inc.). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs 10.7%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs -8.8%).
Mayville Engineering Company, Inc. is a U.S.-headquartered leading manufacturer of metal components, fabricated assemblies, and custom engineered solutions. It serves OEM clients across agriculture, construction, transportation, defense, and power sports markets, offering end-to-end services from prototyping to high-volume production for North America.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
MEC vs TVTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $134.3M | $129.7M |
| Net Profit | $-4.4M | — |
| Gross Margin | 6.8% | 98.0% |
| Operating Margin | -4.1% | -25.0% |
| Net Margin | -3.2% | — |
| Revenue YoY | 10.7% | 73.4% |
| Net Profit YoY | -127.3% | — |
| EPS (diluted) | $-0.22 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $134.3M | $129.7M | ||
| Q3 25 | $144.3M | $164.9M | ||
| Q2 25 | $132.3M | $114.4M | ||
| Q1 25 | $135.6M | $81.7M | ||
| Q4 24 | $121.3M | $74.8M | ||
| Q3 24 | $135.4M | $62.9M | ||
| Q2 24 | $163.6M | $54.1M | ||
| Q1 24 | $161.3M | $41.4M |
| Q4 25 | $-4.4M | — | ||
| Q3 25 | $-2.7M | $25.7M | ||
| Q2 25 | $-1.1M | $-12.8M | ||
| Q1 25 | $20.0K | $-41.2M | ||
| Q4 24 | $16.0M | — | ||
| Q3 24 | $3.0M | $-54.8M | ||
| Q2 24 | $3.8M | $-70.4M | ||
| Q1 24 | $3.2M | $-136.1M |
| Q4 25 | 6.8% | 98.0% | ||
| Q3 25 | 11.0% | 99.0% | ||
| Q2 25 | 10.3% | 98.7% | ||
| Q1 25 | 11.3% | 94.3% | ||
| Q4 24 | 8.9% | 96.6% | ||
| Q3 24 | 12.6% | 97.4% | ||
| Q2 24 | 13.6% | 96.2% | ||
| Q1 24 | 13.0% | 96.4% |
| Q4 25 | -4.1% | -25.0% | ||
| Q3 25 | 0.0% | 15.1% | ||
| Q2 25 | 0.1% | -11.1% | ||
| Q1 25 | 1.2% | -52.2% | ||
| Q4 24 | 19.0% | -81.2% | ||
| Q3 24 | 4.2% | -89.3% | ||
| Q2 24 | 5.0% | -125.1% | ||
| Q1 24 | 4.7% | -336.5% |
| Q4 25 | -3.2% | — | ||
| Q3 25 | -1.9% | 15.6% | ||
| Q2 25 | -0.8% | -11.1% | ||
| Q1 25 | 0.0% | -50.4% | ||
| Q4 24 | 13.2% | — | ||
| Q3 24 | 2.2% | -87.1% | ||
| Q2 24 | 2.3% | -130.1% | ||
| Q1 24 | 2.0% | -328.9% |
| Q4 25 | $-0.22 | $0.04 | ||
| Q3 25 | $-0.13 | $0.28 | ||
| Q2 25 | $-0.05 | $-0.14 | ||
| Q1 25 | $0.00 | $-0.47 | ||
| Q4 24 | $0.76 | $-0.71 | ||
| Q3 24 | $0.14 | $-0.70 | ||
| Q2 24 | $0.18 | $-0.91 | ||
| Q1 24 | $0.16 | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.5M | $93.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $240.7M | $114.8M |
| Total Assets | $563.6M | $605.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.5M | $93.0M | ||
| Q3 25 | $1.2M | $110.9M | ||
| Q2 25 | $206.0K | $75.2M | ||
| Q1 25 | $183.0K | $61.9M | ||
| Q4 24 | $206.0K | $58.5M | ||
| Q3 24 | $178.0K | $36.4M | ||
| Q2 24 | $314.0K | $32.3M | ||
| Q1 24 | $314.0K | $43.3M |
| Q4 25 | $240.7M | $114.8M | ||
| Q3 25 | $244.8M | $73.6M | ||
| Q2 25 | $246.8M | $32.7M | ||
| Q1 25 | $250.0M | $32.8M | ||
| Q4 24 | $251.8M | $59.1M | ||
| Q3 24 | $238.4M | $-30.5M | ||
| Q2 24 | $238.1M | $15.1M | ||
| Q1 24 | $234.0M | $74.1M |
| Q4 25 | $563.6M | $605.2M | ||
| Q3 25 | $585.6M | $538.6M | ||
| Q2 25 | $433.7M | $555.3M | ||
| Q1 25 | $447.7M | $548.8M | ||
| Q4 24 | $445.6M | $594.1M | ||
| Q3 24 | $466.0M | $504.4M | ||
| Q2 24 | $488.2M | $551.1M | ||
| Q1 24 | $499.9M | $663.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.4M | $60.7M |
| Free Cash FlowOCF − Capex | $10.2M | — |
| FCF MarginFCF / Revenue | 7.6% | — |
| Capex IntensityCapex / Revenue | 2.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $26.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $13.4M | $60.7M | ||
| Q3 25 | $1.9M | $14.3M | ||
| Q2 25 | $15.0M | $5.0M | ||
| Q1 25 | $8.3M | $-42.2M | ||
| Q4 24 | $38.0M | $-35.7M | ||
| Q3 24 | $17.9M | $-42.5M | ||
| Q2 24 | $23.3M | $-40.2M | ||
| Q1 24 | $10.6M | $-119.0M |
| Q4 25 | $10.2M | — | ||
| Q3 25 | $-1.1M | $14.2M | ||
| Q2 25 | $12.5M | — | ||
| Q1 25 | $5.4M | — | ||
| Q4 24 | $35.6M | — | ||
| Q3 24 | $15.1M | — | ||
| Q2 24 | $19.2M | $-40.3M | ||
| Q1 24 | $7.8M | — |
| Q4 25 | 7.6% | — | ||
| Q3 25 | -0.8% | 8.6% | ||
| Q2 25 | 9.5% | — | ||
| Q1 25 | 4.0% | — | ||
| Q4 24 | 29.4% | — | ||
| Q3 24 | 11.1% | — | ||
| Q2 24 | 11.7% | -74.5% | ||
| Q1 24 | 4.9% | — |
| Q4 25 | 2.4% | — | ||
| Q3 25 | 2.1% | 0.1% | ||
| Q2 25 | 1.8% | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | 1.9% | — | ||
| Q3 24 | 2.1% | 0.0% | ||
| Q2 24 | 2.5% | 0.2% | ||
| Q1 24 | 1.7% | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.56× | ||
| Q2 25 | — | — | ||
| Q1 25 | 416.65× | — | ||
| Q4 24 | 2.38× | — | ||
| Q3 24 | 6.03× | — | ||
| Q2 24 | 6.15× | — | ||
| Q1 24 | 3.28× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MEC
| Fabrication | $72.2M | 54% |
| Construction And Access | $19.2M | 14% |
| Tubes | $16.2M | 12% |
| Other Market | $11.9M | 9% |
| Agriculture | $7.7M | 6% |
| Military | $6.7M | 5% |
| Outdoor Sports | $1.7M | 1% |
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
